Select Your Region
Global
A Clinical Trial to Compare Targeted Therapy or Cancer Immunotherapy with Chemotherapy in Patients with Cancer of Unknown Primary (CUPISCO)
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Cancer
- Cancer of Unknown Primary (CUP)
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:
Completed
This study runs in
Cities
- Aarhus N
- Adana
- Angers
- Ankara
- Antalya
- Athina
- Augsburg
- Bangkok
- Barcelona
- Barretos
- Basel
- Bath
- Bedford Park
- Bergamo
- Berlin
- Besançon
- Blacktown
- Bogotá
- Bordeaux
- Brno
- Budapest
- Caen
- Cardiff
- Catanzaro
- CD Mexico
- Chiba
- Clermont-Ferrand
- Cluj-Napoca
- Craiova
- Dachau
- Dresden
- Dublin
- Edinburgh
- Edirne
- Essen
- Frankfurt
- Fukuoka
- Graz
- Heidelberg
- Heilbronn
- Helsinki
- Iasi
- Ioannina
- Iraklio
- Istanbul
- Jena
- kar-iyaka
- Kecskemét
- Kraków
- Kristiansand
- København Ø
- Lima
- London
- Lyon
- Lørenskog
- Madrid
- Manchester
- Mannheim
- Marseille Cedex 09
- Melbourne
- Milano
- Monterrey
- Montería
- Montpellier
- Málaga
- München
- Münster
- Napoli
- Newcastle upon Tyne
- Nice
- Oldenburg Holstein
- Olomouc
- Oslo
- Padova
- Pamplona
- Paris
- Petach Tikva
- Pierre-Benite (Lyon)
- Pisa
- Porto
- Praha 2
- Ramat Gan
- Recoleta
- Reggio Emilia
- Rennes
- Riga
- Rio de Janeiro
- Rotterdam
- s-hhiye--ankara
- Salvador
- Salzburg
- Sant Joan Despí
- Seoul
- Sevilla
- Sofia
- South Brisbane
- Southampton
- St Leonards
- Strasbourg
- Suresnes
- São Paulo
- Tallinn
- Tampere
- Tel Aviv
- Temuco
- Thessaloniki
- timi-oara
- Torquay
- Utrecht
- València
- Venlo
- Vigo
- Villejuif
- Waterford
- Wien
- Zagreb
- Zaragoza
- Zürich
Study Identifier:
NCT03498521 2017-003040-20 MX39795
Study Summary
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.
Hoffmann-La Roche
Sponsor
Phase 2
Phase
NCT03498521, MX39795, 2017-003040-20
Study Identifier
Alectinib, Vismodegib, Ipatasertib, Olaparib, Erlotinib, Bevacizumab, Vemurafenib, Cobimetinib, Trastuzumab Subcutaneous (SC), Pertuzumab, Atezolizumab, Carboplatin, Paclitaxel, Cisplatin, Gemcitabine, Entrectinib, Ivosidenib, Pemigatinib
Treatments
Cancer of Unknown Primary Site
Condition
Official Title
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Histologically-confirmed unresectable cancer of unknown primary site (CUP) diagnosed according to criteria defined in the 2015 European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for CUP
- No prior lines of systemic therapy for the treatment of CUP
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Candidate for platinum-based chemotherapy (according to the reference information for the intended chemotherapy)
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
- Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue sample </= 4 months old that is expected to be sufficient for generation of a comprehensive genomic profile at a central reference pathology laboratory
Exclusion Criteria
- Squamous cell CUP
- Participants who can be assigned to a specific subset of CUP for which a specific treatment is recommended by the 2015 ESMO Clinical Practice Guidelines for CUP or with a clinical and IHC profile indicative of a specific primary tumor (favorable prognosis CUP subsets): Poorly differentiated carcinoma with midline distribution; women with papillary adenocarcinoma of the peritoneal cavity; women with adenocarcinoma involving only the axillary lymph nodes; squamous cell carcinoma of the cervical lymph nodes; poorly differentiated neuroendocrine tumors; men with blastic bone metastases and elevated prostate-specific antigen (PSA); participants with a single, small, potentially resectable tumor; colon cancer-type CUP, including participants with a CK7 negative, CK20 positive, CDX-2 positive immunohistochemistry profile; CK7-positive, CK20-negative and TTF-1 positive tumors in a context suggestive of lung adenocarcinoma or thyroid cancer; IHC profile definitely indicative of breast cancer OR an IHC profile indicative of breast cancer and either a history of breast cancer or lymph nodes in the drainage areas of the breast; high-grade serious carcinoma histology and elevated CA125 tumor marker and/or a mass in the gynecological tract or any tumor mass or lymph node in the abdominal cavity; IHC profile suggestive of renal cell carcinoma and renal lesions, with a Bosniak classification higher than IIF; IHC profile compatible with cholangiocarcinoma or pancreatobiliary (or upper gastrointestinal carcinoma) AND 1 or 2 liver lesions without extrahepatic disease or with only pulmonary metastases and/or lymph nodes in the drainage areas of the liver
- Known presence of brain or spinal cord metastasis (including metastases that have been irradiated only)
- Histology and immunohistology profiles (per 2015 ESMO guidelines) that are not adenocarcinoma or poorly differentiated carcinoma/adenocarcinoma
- History or known presence of leptomeningeal disease
- Known human immunodeficiency virus (HIV) infection
- Significant cardiovascular disease
- Prior allogeneic stem cell or solid organ transplantation
- Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or for up to 7 months after the final dose of treatment
For the latest version of this information please go to www.forpatients.roche.com